In this article, we will discuss Cladribine (Dosage Overview). So, let’s get started.
Cladribine is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of Cladribine is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.
Limitations of Use
Cladribine is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.
The recommended cumulative dosage of Cladribine is 3.5 mg per kg body weight administered orally and divided into 2 yearly treatment courses (1.75 mg per kg per treatment course). Each treatment course is divided into 2 treatment cycles:
Administration of First Treatment Course
First Course/First Cycle: start any time.
First Course/Second Cycle: administer 23 to 27 days after the last dose of First
Administration of Second Treatment Course
Second Course/First Cycle: administer at least 43 weeks after the last dose of First Course/Second Cycle.
Second Course/Second Cycle: administer 23 to 27 days after the last dose of Second Course/First Cycle.